Clinical Trials Logo

Ankylosing Spondylitis clinical trials

View clinical trials related to Ankylosing Spondylitis.

Filter by:

NCT ID: NCT02260310 Enrolling by invitation - Clinical trials for Ankylosing Spondylitis

The Effect of Acupuncture Protocol Involving in Weizhong (BL4) and Huantiao (GB30) Points in Treating Ankylosing Spondylitis

Start date: October 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of acupuncture protocol involving in Weizhong (BL4) and Huantiao (GB30) points in treating ankylosing spondylitis.

NCT ID: NCT02260284 Enrolling by invitation - Low Back Pain Clinical Trials

The Effect of Acupuncture in Treating Chronic Low-back Pain

Start date: October 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficiency of acupuncture in treating chronic low-back pain

NCT ID: NCT02202850 Completed - Clinical trials for Ankylosing Spondylitis

Defining Remission With Etanercept in AS in Real Life Clinical Practice

REACH AS
Start date: August 12, 2014
Phase:
Study type: Observational

Determine which remission criterion at Month 6 predicts remission at Month 12 the best.

NCT ID: NCT02201043 Completed - Clinical trials for Ankylosing Spondylitis

Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis

Start date: February 2013
Phase: Phase 2
Study type: Interventional

1. Evaluate the efficacy and safety of taking thalidomide tablets once daily in the treatment of active ankylosing spondylitis. 2. To explore dose-effect relationships of taking thalidomide tablets once daily in the treatment of active ankylosing spondylitis, as well as selecting the appropriate dose for the further larger scale clinical trials.

NCT ID: NCT02186873 Completed - Clinical trials for Ankylosing Spondylitis

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

Start date: September 3, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active ankylosing spondylitis (chronic inflammatory disease of unknown etiology that involves the sacroiliac joints, and often the axial skeleton, entheses, and peripheral joints).

NCT ID: NCT02154425 Completed - Clinical trials for Rheumatoid Arthritis

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

CRADLE
Start date: September 2014
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to assess whether there is transfer of Certolizumab Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing regimen of CZP by evaluating the concentration of CZP in mature breast milk, and to calculate the daily infant dose of maternal CZP.

NCT ID: NCT02132234 Recruiting - Hypertension Clinical Trials

Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Start date: June 2013
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the influence of anti tumor necrosis factor-alpha (TNF-α) treatment on blood pressure, endothelial function and immune cell phenotype in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

NCT ID: NCT02019602 Completed - Clinical trials for Rheumatoid Arthritis

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta

CRIB
Start date: January 2014
Phase: Phase 1
Study type: Interventional

The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of infants at birth.

NCT ID: NCT01988506 Completed - Clinical trials for Rheumatoid Arthritis

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

TRANSREG
Start date: January 6, 2014
Phase: Phase 2
Study type: Interventional

TRANSREG will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a set of 14 autoimmune and auto-inflammatory diseases, with the aim to select diseases in which further therapeutic development will be performed. Extensive biological- and immune-monitoring pre- and post-IL2 will contribute (i) to define the common or distinct processes responsible for the breakdown of immunological tolerance in these pathologies and (ii) to discover potential biomarkers of the IL2 response.

NCT ID: NCT01965132 Recruiting - Clinical trials for Rheumatoid Arthritis

Korean College of Rheumatology Biologics and Targeted Therapy Registry

KOBIO
Start date: December 1, 2012
Phase:
Study type: Observational [Patient Registry]

We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving biologics or targeted synthetic DMARDs. As this registry is to observe the "real world" use of anti-rheumatic treatments under routine clinical practice, no hypothesis to prove is planned.